Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New clinical application of medical composition

A technology of composition and use, applied in the field of medicine, can solve the problem of no relevant research on the effect and the like

Inactive Publication Date: 2010-09-15
北京利乐生制药科技有限公司
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing compound of citicoline and inosine is an injection, which is only used to treat optic atrophy. There is no relevant research on the effect of this compound on other diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New clinical application of medical composition
  • New clinical application of medical composition
  • New clinical application of medical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0008] Pharmacological experiment: the effect of compound citicoline inosine on improving dementia, disturbance of consciousness, learning and memory

[0009] Administration in groups: 40 experimental animals Wistar rats. 30 minutes before the experiment, the dementia animal model was prepared by intraperitoneal injection of scopolamine hydrobromide solution. Then the dementia model mice were randomly divided into 4 groups, 10 in each group: dementia blank model group (A); compound citicoline inosine group (B), citicoline group (C), inosine group (D ). After 30 minutes, the drug was started, and the compound citicoline inosine 200mg (the ratio of citicoline and inosine was 3:2) was administered orally twice a day, citicoline 200mg was administered orally twice a day, and inosine 200 mg orally twice a day; and according to the treatment time, it will be divided into four time periods of 30, 60.90, and 120 days for research. Experimental method: (1) Learning ability test: All...

Embodiment 2

[0015] Pharmacological experiment: Observing the protective effect of compound citicoline inosine on focal cerebral ischemia in rats

[0016] Experimental method: 50 rats were taken and randomly divided into 5 groups, compound citicoline inosine group (0.1g / kg), citicoline group (0.1g / kg), inosine group (0.1g / kg ), model control group and sham operation group, 10 rats in each group. Each group was administered intragastrically before modeling, once a day, for a total of 4 days, and the volume of administration was 10ml / kg. The model control group and the sham operation group were given equal volume of normal saline. Model making method: 1 hour after the last administration, rats were anesthetized by intraperitoneal injection of 10% chloral hydrate (350ms / kg), fixed in supine position, routinely disinfected skin, midline incision of the neck, and blunt separation of the right common carotid artery and carotid artery. external and internal carotid arteries. The pterygopalatin...

Embodiment 3

[0027] Pharmacological Experiment: Behavioral Pharmacological Effects of Compound Citicoline Adenosine on Parkinson's Model in Mice

[0028] Experimental method: 100 male C57BL small black mice were selected and randomly divided into normal saline (Ns) group, MPTP (M) group, compound citicoline adenosine+MPTP group (F+M), citicoline+ MPTP group (C+M), adenosine+MPTP group (I+M), 20 rats in each group. On the first day of the experiment, the F+M group, C+M group and I+M group were intraperitoneally injected with compound citicoline adenosine, citicoline and adenosine respectively; on the second day, the F+M group, C+M group and The I+M group was injected intraperitoneally with compound citicoline adenosine, citicoline and adenosine (the dose was the same as the first day), and 20 minutes later, the MPTP group was injected with MPTP36mg / kg intraperitoneally, and the NS group was intraperitoneally injected with the same volume of Normal saline, operated continuously for 7 days. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to new clinical application of a medical composition, in particular to the application of the composition formed from citicoline salt and inosine or adenosine in preparing medicines for treating cerebrovascular dysfunctions, craniocerebral injuries, dementia, Parkinsonism and heart diseases, wherein the unit dosage of the citicoline salt is 0.01g-2.5g, and the unit dosage of the inosine is 0.005g-2g. When in use, the medical composition can be prepared into compound preparations, including oral preparations and injection preparations for application.

Description

technical field [0001] The present invention is a new clinical application of a pharmaceutical composition, which is a composition formed of citicoline salt and inosine or adenosine in the preparation and treatment of cerebrovascular dysfunction, craniocerebral injury, dementia and Parkinson's syndrome , Application in heart disease medicine. It belongs to the field of medical technology. Background technique [0002] Citicoline is currently the most clinically used nerve activator, an intermediate in the endogenous synthesis of phosphatidylcholine, and an important component in the construction of biofilms. After the central nervous system is injured, citicoline participates in the repair and regeneration and plays a neuroprotective role; it also plays an important role in the transfer of nerve media and the conduction of bioelectricity. Citicoline is a nucleoside derivative, which can also reduce cerebrovascular resistance, increase cerebral blood flow and promote brain ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/708A61K31/7068A61K31/7076A61P9/10A61P25/28A61P25/16A61P9/00
Inventor 王晓丹
Owner 北京利乐生制药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com